TY - JOUR
T1 - Diagnostic Dilemmas in Pulmonary Hypertension
AU - Frantz, Robert P.
AU - McGoon, Michael D.
N1 - Funding Information:
Financial Disclosures: Dr Frantz's institution has received research funding from Medtronic , Inc, Actelion Pharmaceuticals, Ltd, United Therapeutics Corporation, and Gilead Sciences, Inc. He has served on advisory boards for United Therapeutics Corporation, Actelion Pharmaceuticals, Ltd, and Gilead Sciences, Inc. Any honoraria for these activities have streamed to Mayo Foundation research accounts in keeping with institutional policy for investigators. Dr McGoon's institution has received research funding from Medtronic, Inc, and Gilead Sciences, Inc He currently serves on advisory, steering, and/or endpoint/DSMB committees for Actelion Pharmaceuticals, Ltd, Gilead Sciences, Inc, Lung Rx, LLC, and GlaxoSmithKline. He is Chair of the REVEAL Registry (funded by Actelion Pharmaceuticals, Ltd). He has received honoraria for speaking at conferences supported by Actelion Pharmaceuticals, Ltd and Gilead Sciences, Inc. The authors' institution receives pulmonary arterial hypertension–related research funding from Actelion Pharmaceuticals , Ltd, Gilead Sciences, Inc, Medtronic, Inc, Pfizer Inc, United Therapeutics Corporation, Novartis Pharmaceuticals Corporation, SHAPE Medical Systems, Inc, and Bayer HealthCare Pharmaceuticals.
PY - 2012/7
Y1 - 2012/7
N2 - Dilemmas persist in the screening, assessment, and follow-up of patients with pulmonary hypertension, relating to issues of whom and how to screen, how to resolve ambiguities in the clinical classification of patients with multiple potential substrates of pulmonary vascular disease, how to interpret test results, how to integrate multiple clinical parameters into a global diagnosis, how to use ambiguous test results, how to determine disease severity and prognosis, and how to monitor patients on treatment. This article describes how to incorporate available information into the diagnostic process, and where lack of concrete data should impose caution in patient management.
AB - Dilemmas persist in the screening, assessment, and follow-up of patients with pulmonary hypertension, relating to issues of whom and how to screen, how to resolve ambiguities in the clinical classification of patients with multiple potential substrates of pulmonary vascular disease, how to interpret test results, how to integrate multiple clinical parameters into a global diagnosis, how to use ambiguous test results, how to determine disease severity and prognosis, and how to monitor patients on treatment. This article describes how to incorporate available information into the diagnostic process, and where lack of concrete data should impose caution in patient management.
KW - Diagnosis
KW - Pulmonary arterial hypertension
KW - Pulmonary hypertension
UR - http://www.scopus.com/inward/record.url?scp=84863096637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863096637&partnerID=8YFLogxK
U2 - 10.1016/j.hfc.2012.04.006
DO - 10.1016/j.hfc.2012.04.006
M3 - Review article
C2 - 22748898
AN - SCOPUS:84863096637
SN - 1551-7136
VL - 8
SP - 331
EP - 352
JO - Heart Failure Clinics
JF - Heart Failure Clinics
IS - 3
ER -